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Pulmonary Embolism in Patients Hospitalized With
COVID-19 (From a New York Health System)
Hai Xu, MD, Angel Martin, MD, Avneet Singh, MD, Mangala Narasimhan, DO, Joe Lau, MD,
Mitchell Weinberg, MD, Rajiv Jauhar, MD, and Gaurav Rao, MD*
Pulmonary embolisms (PEs) in coronavirus disease 2019 (COVID-19) have increasingly
been reported in observational studies. However, limited information describing their
clinical characteristics and outcomes exists. Our study aims to describe clinical features
and risk stratification strategies of hospitalized COVID-19 patients with PE. We retrospectively analyzed 101 hospitalized patients with COVID-19 infection and acute PE. Clinical outcomes measured were intensive care unit admission, mechanical ventilation,
bleeding and transfusion events, acute kidney injury (AKI) and mortality. Pulmonary
severity index (PESI) scores were used for risk stratification. The most common comorbidities were hypertension (50%), obesity (27%) and hyperlipidemia (32%) among this
cohort. Baseline D-dimer abnormalities (4,647.0 § 8,281.8) were noted on admission with
a 3-fold increase at the time of PE diagnosis (13,288.4 § 14,917.9; p <0.05). Five (5%)
patients required systemic thrombolysis and 12 (12%) patients experienced moderate to
severe bleeding. Thirty-one (31%) patients developed AKI and 1 (1%) patient required
renal replacement therapy. Twenty-three (23%) patients were admitted to intensive care
unit, of which 20 (20%) patients received mechanical ventilation. The mortality rate was
20%. Most patients (65%) had Intermediate to high risk PESI scores (>85), which portended a worse prognosis with higher mortality rate and length of stay. In conclusion, this
study provides characteristics and early outcomes for hospitalized patients with COVID19 and acute pulmonary embolism. PESI scores were utilized for risk stratifying clinical
outcomes. Our results should serve to alert the medical community to heighted vigilance
of this VTE complication associated with COVID-19 infection. © 2020 Elsevier Inc. All
rights reserved. (Am J Cardiol 2020;133:148−153)

INTRODUCTION
The novel 2019 coronavirus disease (COVID-19) has led
to a global pandemic with a spectrum of clinical manifestations among infected patients.1 Cardiopulmonary injury
related to this viral infection is now recognized as a common feature resulting in high mortality.2 Prior cardiovascular comorbidities, such as obesity, diabetes, hypertension,
and coronary artery disease, portend a poor prognosis
amongst these patients.3 An association of COVID-19
infection with venous thromboembolic events (VTEs) has
increasingly been recognized by observational studies outside the United States.4,5 This was further corroborated by
high incidences of VTE findings, such as clinically overlooked pulmonary embolism, on autopsy.6 COVID-19 creates a hypercoagulable milieu due to exaggerated
inflammatory response and, thus, leads to a coagulation disarray, as evidenced by elevated inflammatory markers
including D-dimer.7−9 However, such a correlation has not
been systemically studied or published to date. We present
our experience, including demographics, clinical characteristics, and outcomes, in COVID-19 patients who also

Donald and Barbara Zucker School of Medicine at Hofstra/Northwell,
Hempstead, New York. Manuscript received June 15, 2020; revised manuscript received and accepted July 17, 2020.
*Corresponding author: Tel: 516-562-1427; fax: 516-562-3992.
E-mail address: Gaurav.j.rao@gmail.com (G. Rao).
0002-9149/© 2020 Elsevier Inc. All rights reserved.
https://doi.org/10.1016/j.amjcard.2020.07.036

developed confirmed pulmonary embolisms during the
course of their initial COVID-19 illness.
Methods
This study was conducted at North Shore University
Hospital and Long Island Jewish Hospital, 2 tertiary medical centers within the Northwell Health system. Both hospitals are located in Queens and Long Island area with
catchment areas encompassing Brooklyn and Queens, NY,
an epicenter for COVID-19 in March and April of 2020.
Institutional review board approval was obtained via the
COVID-19 Consortium at Northwell Health. Hospitalized
patients with confirmed COVID-19 positive results on polymerase chain reaction testing, as well as confirmed PE by
computed tomography angiogram were included. All studied patients were admitted between March 1, 2020, and
April 30, 2020. Clinical outcomes were monitored until
May 14, 2020, the final date of follow-up. The presenting
characteristics of 5,700 patients from Northwell were presented previously.10 This cohort presents a further in-depth
assessment of clinical features and outcomes in COVID-19
positive patients with concurrent PE not presented in the
prior article.
Data was retrospectively collected from the enterprise
electronic health record (Sunrise Clinical Manager; Allscripts). Patients’ demographic information, comorbidities
and laboratory tests at the time of COVID-19 diagnosis
were recorded through chart review. Obesity was defined as
www.ajconline.org
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having a body mass index (BMI) >30. Hypertension, hyperlipidemia, and diabetes status was assessed through clinical
chart documentation and medication reconciliation. Vital
signs, electrocardiogram, laboratory tests, and relevant
imaging were obtained at the time of PE diagnosis. These
clinical parameters were used to calculate individual PESI
scores. RV strain by CT was defined as a right ventricle to
left ventricle size ratio of 0.9 or greater. RV dysfunction on
transthoracic echocardiography was diagnosed through
qualitative and quantitative RV dilation or RV systolic dysfunction as assessed by a board certified echocardiographer.
Clinical outcomes recorded were the use of systemic
thrombolysis, mechanical ventilation, intensive care unit
(ICU) admission, stroke, deep venous thromboembolism
(DVT), bleeding events, transfusion event, acute kidney
injury (AKI), renal replacement therapy, and mortality.
Bleeding events were classified by the GUSTO (global utilization of streptokinase and tissue plasminogen activator
for occluded coronary arteries) bleeding criteria.11 Acute
kidney injury, based on the kidney disease: improving
global outcomes (DKIGO) definition, was identified as an
increase in serum creatinine to 1.5 times or more baseline
within the prior 7 days compared with the preceding 1 year
of data, or an increase in serum creatinine by 0.3 mg/dL or
more within 48 hours.12 Additionally, D-dimer measurements at COVID-19 diagnosis and the time of PE diagnosis
were recorded, both within 24 hours of events. Similar analyses were made to study vital sign variations from the time
of admission to the time of PE diagnosis. Finally, we risk
stratified outcomes based on PESI score into low risk
(PESI ≤85) and intermediate to high risk (PESI >85) for
comparison.
Statistical analysis was performed by means of Fisher’s
exact test in categorical variables, pertaining mostly to
patient clinical outcomes. Within group comparisons of
continuous variables, that is comparison of d-dimer values
at times of COVID-19 and PE diagnoses, were performed
with the paired-sample t test. Continuous data are presented
as mean § standard deviation and sample proportions are
reported as percentages. P values were reported as 2-sided,
and a p value < 0.05 was considered statistically significant.
All statistical analyses were performed with the use of
SPSS software version 23 (IBM, Armonk, New York).
Results
A total of 101 patients were included in this study
(Figure 1). Basic demographics including mean age, gender
and ethnicity distributions are presented in Table 1. The
most common comorbidities were hypertension, obesity,
hyperlipidemia, diabetes mellitus, smoking history and previous VTE, which was similar to the larger Northwell experience.10 All hospitalized patients were on prophylactic
anticoagulation as per health system policy in patients with
COVID-19 infection, with 12 patients continued on their
home anticoagulation regimen.
At the time of COVID-19 diagnosis on admission, 53
(52%) patients exhibited bilateral patchy opacities on presenting chest x-ray, consistent with viral pneumonia infection (Table 2). Significant elevation in inflammatory
markers was noted on admission. The baseline D-dimer
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Figure 1. Flowchart of the study enrollment.

increased by 3-fold (13,288 § 14,918 ng/ml) within
24 hours of PE diagnosis. Intra-group comparison among
patients who had both measurements demonstrated significant rise (p <0.05) from the time of COVID-19 diagnosis to
the time of acute PE diagnosis (Figure 2). Additionally, 34
patients had elevated troponin on admission (27.7 § 25 ng/

Table 1
Baseline characteristics of COVID-19 patients with acute PE diagnosis*
Variable
Mean age (years)
Men
Women
White
Black
Asian
Other, multiracial
Current smoker
Obesityy
Diabetes mellitus
Hypertension
Hyperlipidemiaz
Cancer
Asthma
Chronic obstructive pulmonary disease
Coronary arterial disease/peripheral
vascular disease/cerebrovascular accident
Atrial fibrillation
Heart failure
Venous Thromboembolism
Anti-platelet, anticoagulation therapy

N = 101
62 (§ 15)
74 (73%)
27 (27%)
28 (28%)
33 (33%)
17 (17%)
23 (23%)
18 (18%)
27 (27%)
18 (18%)
51 (50%)
32 (32%)
13 (13%)
6 (6%)
4 (4%)
15 (15%)
6 (6%)
5 (5%)
11 (11%)
21 (21%)

* Values presented as no. (%) or mean (§ standard deviation) where
appropriate. Age refers to the age at study enrollment.
y
Obesity defined as body mass index greater than or equal to 30.0 kg/m2.
z
Assessed based on a diagnosis of hyperlipidemia/dyslipidemia in medical history by ICD-10 coding.
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Table 2
Findings at times of COVID-19 and pulmonary embolism diagnoses*
Variable
On admission
Bilateral patchy opacity (X-ray)
White blood cell (109/L)
Lymphocyte (109/L)
Platelet (109/L)
Sodium (mmol/L)
Creatinine (mg/dL)
Aspartate aminotransferase (U/L)
Alanine aminotransferase (U/L)
Lactate dehydrogenase (U/L)
Ferritin (ng/mL)
C-reactive protein (mg/dL)
International normalized ratio
D-dimer (ng/ml)
At the time of PE diagnosis
Tachycardia
Hypotension
Hypoxia
Fever
Sinus tachycardia
Supraventricular tachycardia
Right bundle branch block
Right ventricular strain pattern
S1Q3T3 pattern
Pulmonary Computed Tomography Angiography:
Saddle embolism
Bilateral PE
Right ventricular strain
Transthoracic echocardiographyy: Ejection fraction (%)
Right ventricle dysfunction
Left ventricular dysfunction
Pulmonary arterial
systolic pressure (mmHg)
Intracardiac thrombus
Pulmonary Embolism Class: Low risk
Sub-massive
Massive
D-dimer (ng/ml)
High sensitivity troponin (ng/L)
Creatine kinase (U/L)
Brain-type natriuretic peptide (pg/mL)

N = 101
53 (52%)
9.5 (§ 4.5)
1.0 (§ 0.9)
265.0 (§ 98.0)
135.5 (§ 5.8)
1.1 (§ 0.5)
56.0 (§ 44.0)
51.0 (§ 46.0)
558.5 (§ 283.8)
1467.2 (§ 1314.0)
66.5 (§ 90.6)
1.3 (§ 0.2)
4647.0 (§ 8281.8)
36 (36%)
3 (3%)
71 (70%)
8 (8%)
38 (38%)
5 (5%)
17 (17%)
15 (15%)
9 (%)

Reference Ranges

3.8 − 10.5
1.0 − 3.3
150 − 450
135 − 145
0.5 − 1.2
10 − 40
10 − 45
50 − 242
15 − 400
0 − 10
0.9 − 1.2
0 − 229
Definitions
Heart rate > 100 BPM
Systolic < 90 mmHg
O2 saturation < 90%
Body temp > 38 ˚C

2 (2%)
47 (47%)
47 (47%)
48.8 (§ 26.3)
14 (34%)
5 (12%)
37.1 (§ 18.7)
3 (7%)
23 (23%)
75 (75%)
3 (3%)
13288.4 (§ 14917.9)
49.1 (§ 141.0)
221.0 (§ 319.0)
1890.5 (§ 2875.0)

0 - 229
<6 − 14
25 − 200
0 − 99

* Values are presented as no (%) or mean (§ standard deviation) where applicable.
y
Transthoracic studies performed in 41 patients. Calculated percentages for right and left ventricular dysfunction, as well as Ejection fraction was based on
this number of patients. Pulmonary arterial systolic pressure was only able to be estimated on 29 patients as tricuspid regurgitation velocity envelope were
not well visualized in the other cases.

L) and this number rose to 48 at the time of PE diagnosis
(49.1 § 141 ng/L).
Average time from hospital admission to PE diagnosis
was 5 days (§ 6.1). At the time of PE diagnosis, tachycardia, hypotension, hypoxia, and fever were most frequently
reported physical exam findings (Table 2). EKG rhythm at
time of PE diagnosis was most commonly sinus tachycardia
followed by atrial fibrillation or atrial flutter. The McGinnWhite sign of S1Q3T3 pattern was observed in 9 patients
(9%).13 RV strain on CT was noted in approximately half
of this cohort with an estimated mean pulmonary artery systolic pressure (PASP) of 37.1 mmHg. Based on imaging
findings, vital signs and biomarker measurements, 75

patients (75%) were diagnosed with sub-massive PE and 3
patients (3%) were diagnosed with massive PE.
At the final study follow-up date, all 101 patients (100%)
received full dose anticoagulation therapy (Table 3).
Twenty-three patients (23%) were admitted to ICU, with 20
(20%) ultimately requiring invasive mechanical ventilation.
Five (5%) patients received systemic thrombolysis. Indication for thrombolytic therapy was hemodynamic instability
in 2 patients and presence of intra-cardiac thrombus with
clot in transit in another 3 patients. No patient received
catheter-directed thrombolysis or thrombectomy. A total of
12 patients experienced moderate or severe bleeding incidents: there were 7 severe cases, including 3 intracranial
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end of the study, 2 of whom were in the ICU on mechanical
ventilation.
Intermediate to high risk PESI score patients (Class 3, 4
and 5) had worse outcomes compared to patients with low
risk PESI scores (Class 1 & 2), resulting in higher percentage ICU admission (29% vs 11%;p = 0.038), longer LOS
(14.3 vs 9.7 days; p = 0.030) and higher mortality rate (27%
vs 6%;p = 0.007). There was no significant variation
between intermediate and high risk groups with respect to
mechanical ventilation use, AKI, bleeding events, thromboembolic incidents including stroke and DVT (p >0.05).
Discussion

Figure 2. D-dimer rise between COVID diagnosis and PE diagnosis. Average D-dimer level was >18x the upper limit of normal (ULN) at the time
of COVID-19 diagnosis on admission (4,647.0 ng/ml § 8,281.8) with a
significant 3-fold increase at the time of PE diagnosis to >57x ULN
(13,288.4 ng/ml § 14,917.9; p <0.05).

(IC) hemorrhages and one of which was fatal. Within this
group, another patient had severe gastrointestinal bleeding
in the context of previous systemic thrombolytic use. Additionally, there were 5 moderate bleeding incidents, of which
2 patients required blood transfusions. Thirteen (13%)
patients were found to have concomitant DVT, although
only 36 patients underwent venous ultrasound study largely
due to selection bias. Overall mean length of stay (LOS)
was 13 days. Six patients remained in the hospital at the

To our knowledge, this cohort represents the largest collection of COVID-19 patients with concurrent pulmonary
embolism. As reported in prior COVID-19 studies, our
patients were more likely to have cardiovascular disease
risk factors such as hypertension, hyperlipidemia, obesity,
diabetes mellitus, and smoking history.14 Only a small percentage of our patients had previous VTEs or malignancies.
Direct effects of COVID-19 or its sequela, via severe
inflammatory response and hypoxia, are postulated to be
the main drivers of pulmonary thrombotic events in our
patients.15,16
Compare with the larger Northwell series,10 our cohort
had higher rates of ICU admission, mechanical ventilation,
AKI and mortality, suggesting the addition of pulmonary
embolism to COVID-19 exacerbates morbidity and mortality. Additionally, the majority of this cohort had PESI
scores >85, which has previously been shown to predict
higher short-term adverse events and mortality.17 When we
applied such risk predictor to this COVID-19 population,
high risk patients required significantly more ICU level
care, increased LOS in the hospital, and experienced a
higher mortality rate. To our knowledge, our study is the

Table 3
Clinical intervention and outcomes based on PESI risk stratification*
Variable
Anticoagulation: Heparin
Enoxaparin
Argatroban
Direct oral
anticoagulant
Thrombolytic use: Full dose
Half dose
Transfusion
Renal replacement therapy
Intensive care unit admission
Mechanical Ventilation
Length of hospital stay, daysy
Acute kidney injury
Bleeding: Severe
Moderate
Deep Venous Thromboembolism
Strokez
Mortality

Total (N = 101)

PESI ≤ 85 (n = 35)

PESI > 85 (n = 66)

P value

25 (25%)
69 (69%)
4 (4%)
3 (3%)

4 (11%)
29 (83%)
1 (3%)
1 (3%)

21 (31%)
40 (60%)
4 (5%)
3 (4%)

0.084

3 (3%)
2 (2%)
9 (9%)
1 (1%)
23 (23%)
20 (20%)
13.0 (§ 10.2)
31 (31%)
7 (7%)
5 (5%)
13 (13%)
3 (3%)
20 (20%)

1 (3%)
0
3 (9%)
0
4 (11%)
4 (11%)
9.7 (§ 5.4)
7 (20%)
2 (6%)
1 (3%)
3 (9%)
0
2 (6%)

2 (3%)
2 (3%)
6 (9%)
1 (2%)
19 (29%)
16 (24%)
14.3 (§ 11.6)
24 (36%)
5 (8%)
4 (5%)
10 (15%)
3 (4%)
18 (27%)

0.794

* Values are presented as no (%) or mean (§ standard deviation) where applicable.
y
At the final study follow-up date, 6 patients remain admitted in the hospital.
z
All 3 patients had acute hemorrhagic stroke and, thus, were also accounted for under severe bleeding events.

0.621
0.653
0.038
0.099
0.030
0.069
0.893
0.347
0.257
0.007
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first to suggest that high PESI scores represent a poor prognostic indicator in COVID-19 patients who develop
acute PE.
We report an overall low incidence of DVT and ischemic stroke in our studied population, although diagnostic
testing was limited in an effort to minimize personnel exposure and viral transmission. This observation may suggest
that localized in situ pulmonary thrombosis, rather than
embolism, occurs among these COVID-19 patients. Similar
findings were reported by Susan et al in their case series of
22 patients with confirmed PE and COVID-19.18 Lung
pathology studies corroborate this finding, with reports of
widespread vascular thrombosis with microangiopathy and
intussusceptive angiogenesis.19 COVID-19 is now widely
considered as a pro-thrombotic disease with systemic
inflammation,20,21 as demonstrated in our cohort by inflammatory marker elevation. The average D-dimer level in our
patients upon initial COVID-19 diagnosis was >18x the
upper limit of normal, with a significant 3-fold increase at
the time of PE diagnosis to a mean D-dimer of >57x ULN
in this cohort. This finding coincides with prior data, which
reported elevated D-dimer levels correlate with the presence of VTE in COVID-19 patients as well as the severity
of infection.8,22,23 Furthermore, Tang et al reported that
patients with higher D-dimer (>6x ULN) have an increasing mortality benefit with anticoagulation.22 Our study suggests a benefit to trend D-dimer levels from initial
admission to aid in early recognition of PE and subsequent
prompt initiation of anticoagulation for maximal therapeutic benefit.22,24
Most patients (75%) in this cohort were categorized as
having sub-massive PE, with either positive cardiac biomarkers or RV dysfunction on imaging. It has been shown
that COVID-19 and its sequela of ARDS managed with
high positive end expiratory pressure can exert detrimental
effects on the myocardium and right ventricular function.25
It is also worth noting these findings predict adverse shortand long-term outcomes in the PE population.26 Given the
high rate of sub-massive PE in our cohort, we emphasize
the importance of increased clinical awareness, as well as
early imaging testing for expeditely diagnosing PE in
COVID-19 patients. All patients require therapeutic anticoagulation, when PE diagnosis is highly suspected based on
clinical context, D-dimer values, and imaging results, with
escalation to potential thrombolytic therapy when indicated
clinically. Based on this practice strategy, we report an
overall small number of bleeding events in our group.
Understanding the potential adverse effects of severe hemorrhage and mortality associated, the benefits of anticoagulation should still be balanced with bleeding risks on an
individual basis
Our study is limited by its inherent retrospective
nature. Only patients who were stable enough to undergo
CTA were analyzed, resulting in unavoidable selection
bias. Similarly, patients with acute kidney injury, which
commonly co-exists in COVID-19, were excluded in an
effort to prevent contrast nephropathy. In an attempt to
curtail viral transmission, many of these patients underwent alternative diagnostic testing such as point of care
ultrasound to evaluate right ventricle dilatation or dysfunction. Such testing results are frequently ambiguous

and difficult to capture for our cohort. For all the aforementioned reasons, PE was likely underestimated in our
institutional dataset.
In conclusion, acute pulmonary embolism is increasingly
being recognized as a complication of active COVID-19
infection. Our results suggest the use of PESI scores and Ddimer measurements for risk stratification and management
guidance in this patient population.
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